Gov. Tony Evers and the Wisconsin Economic Development Corp. (WEDC) today announced that the state will support Eli Lilly and Co.’s $4 billion investment in Wisconsin with up to $100 million in performance-based state tax credits.
Last year, Evers joined Eli Lilly officials to announce that the expansion project in Bristol will extend the company’s global parenteral (injectable) product manufacturing network, helping to meet the growing demand for diabetes, obesity and future pipeline medicines across therapeutic areas. Lilly expects to add 750 jobs to the current 100-plus workforce at this location.
The Evers Administration, through WEDC, began working on the expansion with the company and local leaders last year, following Eli Lilly’s acquisition of a sterile injectables manufacturing plant in Pleasant Prairie owned by Nexus Pharmaceuticals.
WEDC had also assisted Nexus Pharmaceuticals in moving its manufacturing operations from Illinois to Wisconsin in 2019. The acquisition, expansion and additional purchases of land and an adjacent warehouse bring Eli Lilly’s total planned investment in Wisconsin to $4 billion.
WEDC will support Eli Lilly’s current expansion with up to $100 million in Enterprise Zone tax credits. The amount of credits the company receives is contingent upon its meeting job creation and capital investment goals.
